2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
70
TL;DR: In 2018, the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions as discussed by the authors .
read more
Abstract: Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide and the fourth most common cancer among men in South Korea, where the prevalence of chronic hepatitis B infection is high in middle and old age. The current practice guidelines will provide useful and sensible advice for the clinical management of patients with HCC. A total of 49 experts in the fields of hepatology, oncology, surgery, radiology, and radiation oncology from the Korean Liver Cancer Association-National Cancer Center Korea Practice Guideline Revision Committee revised the 2018 Korean guidelines and developed new recommendations that integrate the most up-to-date research findings and expert opinions. These guidelines provide useful information and direction for all clinicians, trainees, and researchers in the diagnosis and treatment of HCC.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Additional file 1 of Trends in alcohol use and alcoholic liver disease in South Korea: a nationwide cohort study
Yoo Jeong Ju,Lee Dong-Hyeon,Chang-young,Cho Young Youn,Lee, Sang-Heun,Jang Jae Young +5 more
- 11 Jul 2024
Abstract: Supplementary Material 1.
Local ablation for hepatocellular carcinoma: 2024 expert consensus-based practical recommendation of the Korean Liver Cancer Association
Seungchul Han,Pil Soo Sung,Soo Young Park,Jin Woong Kim,Hyun Pyo Hong,Jung-Hee Yoon,Dong Jin Chung,Joon Ho Kwon,Sanghyeok Lim,Jae Hyun Kim,Seung Kak Shin,Tae Hyung Kim,Dong Ho Lee,Jong Young Choi +13 more
TL;DR: The Korean Liver Cancer Association provides a 2024 expert consensus-based practical recommendation for local ablation of hepatocellular carcinoma, standardizing patient selection, procedural methods, and post-treatment management for improved safety and effectiveness.
Diagnostic performance of the 2022 KLCA-NCC criteria for hepatocellular carcinoma on magnetic resonance imaging with extracellular contrast and hepatobiliary agents: comparison with the 2018 KLCA-NCC criteria
TL;DR: In this article , the diagnostic performance of 2022 Korean Liver Cancer Association-National Cancer Center (KLCA-NCC) imaging criteria compared with the 2018 KLCA NCC for hepatocellular carcinoma (HCC) in high-risk patients using magnetic resonance imaging (MRI).
Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis.
Yunmi Ko,Moon-Haeng Hur,Eun Ju Cho +2 more
TL;DR: The effectiveness of atezolizumab plus bevacizumab and lenvatinib was comparable for the treatment of HCC with PVTT, and HRs were similar after inverse probability treatment weighting.
Sonazoid contrast-enhanced ultrasonography for the diagnosis of hepatocellular carcinoma: strengths and shortcomings.
Sung Won Lee,Min Kyu Kang,Xiang Zhang +2 more
TL;DR: Sonazoid contrast-enhanced ultrasonography for the diagnosis of hepatocellular carcinoma: strengths and shortcomings is presented.
References
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
26.9K
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt,Andrew D Oxman,Gunn Elisabeth Vist,Regina Kunz,Yngve Falck-Ytter,Pablo Alonso-Coello,Holger J. Schünemann +6 more
TL;DR: The advantages of the GRADE system are explored, which is increasingly being adopted by organisations worldwide and which is often praised for its high level of consistency.
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010
Rafael Lozano,Mohsen Naghavi,Kyle J Foreman,Stephen S Lim,Kenji Shibuya,Victor Aboyans,Jerry Abraham,Tim Adair,Rakesh Aggarwal,Stephanie Y. Ahn,Mohammad A. AlMazroa,Miriam Alvarado,H. Ross Anderson,Laurie M. Anderson,Kathryn G. Andrews,Charles Atkinson,Larry M. Baddour,Suzanne Barker-Collo,David Bartels,Michelle L. Bell,Emelia J. Benjamin,Derrick A Bennett,Kavi Bhalla,Boris Bikbov,Aref A. Bin Abdulhak,Gretchen L. Birbeck,Fiona M. Blyth,Ian Bolliger,Soufiane Boufous,Chiara Bucello,Michael Burch,Peter Burney,Jonathan R. Carapetis,Honglei Chen,David Chou,Sumeet S. Chugh,Luc E. Coffeng,Steven D. Colan,Samantha M. Colquhoun,K. Ellicott Colson,John R. Condon,Myles Connor,Myles Connor,Leslie T. Cooper,Matthew A. Corriere,Monica Cortinovis,Karen Courville De Vaccaro,William G. Couser,Benjamin C Cowie,Michael H. Criqui,Marita Cross,Kaustubh Dabhadkar,Nabila Dahodwala,Diego De Leo,Louisa Degenhardt,Allyne Delossantos,Julie O. Denenberg,Don C. Des Jarlais,Samath D Dharmaratne,Samath D Dharmaratne,E. Ray Dorsey,Tim Driscoll,Herbert C. Duber,Beth E. Ebel,Patricia J. Erwin,Patricia Espindola,Majid Ezzati,Valery L. Feigin,Abraham D. Flaxman,Mohammad H. Forouzanfar,F.G.R. Fowkes,Richard C. Franklin,Marlene Fransen,Michael Freeman,Sherine E. Gabriel,Emmanuela Gakidou,Flavio Gaspari,Richard F. Gillum,Diego Gonzalez-Medina,Yara A. Halasa,Diana Haring,James Harrison,Rasmus Havmoeller,Rasmus Havmoeller,Roderick J. Hay,Bruno Hoen,Peter J. Hotez,Damian G Hoy,Kathryn H. Jacobsen,Spencer L. James,Rashmi Jasrasaria,Sudha Jayaraman,Nicole E. Johns,Ganesan Karthikeyan,Nicholas J Kassebaum,Andre Keren,Jon Paul Khoo,Lisa M. Knowlton,Olive Kobusingye,Adofo Koranteng,Rita Krishnamurthi,Michael S Lipnick,Steven E. Lipshultz,Summer Lockett Ohno,Jacqueline Mabweijano,Jacqueline Mabweijano,Michael F. Macintyre,Leslie Mallinger,Lyn March,Guy B. Marks,Robin Marks,Akira Matsumori,Richard Matzopoulos,Richard Matzopoulos,Bongani M. Mayosi,John H. McAnulty,Mary M. McDermott,John J. McGrath,Ziad A. Memish,George A. Mensah,Tony R. Merriman,Catherine Michaud,Matthew J. Miller,Ted R. Miller,Charles Mock,Ana Olga Mocumbi,Ali A. Mokdad,Andrew E. Moran,Kim Mulholland,M. Nathan Nair,Luigi Naldi,K.M. Venkat Narayan,Kiumarss Nasseri,Paul Norman,Martin O'Donnell,Saad B. Omer,Katrina F Ortblad,Richard H. Osborne,Doruk Ozgediz,Bishnu Pahari,Jeyaraj D Pandian,Andrea Panozo Rivero,Rogelio Perez Padilla,Fernando Perez-Ruiz,Norberto Perico,David Phillips,Kelsey Pierce,C. Arden Pope,Esteban Porrini,Farshad Pourmalek,Murugesan Raju,Dharani Ranganathan,Jürgen Rehm,David B. Rein,G. Remuzzi,Frederick P. Rivara,Thomas Roberts,Felipe Rodriguez De Leòn,Lisa C. Rosenfeld,Lesley Rushton,Ralph L. Sacco,Joshua A. Salomon,Uchechukwu Sampson,Ella Sanman,David C. Schwebel,Maria Segui-Gomez,Donald S. Shepard,David Singh,Jessica Singleton,Karen Sliwa,Emma Smith,Andrew C Steer,Jennifer A. Taylor,Bernadette Thomas,Imad M. Tleyjeh,Jeffrey A. Towbin,Thomas Truelsen,Eduardo A. Undurraga,Narayanaswamy Venketasubramanian,Lakshmi Vijayakumar,Theo Vos,Gregory R. Wagner,Mengru Wang,Wenzhi Wang,Kerrianne Watt,Martin A. Weinstock,Robert G. Weintraub,James D. Wilkinson,Anthony D. Woolf,Sarah Wulf,Pon Hsiu Yeh,Paul S. F. Yip,Azadeh Zabetian,Zhi Jie Zheng,Alan D. Lopez,Christopher J L Murray +195 more
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex, using the Cause of Death Ensemble model.
14.1K
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Related Papers (5)
T. Hasegawa,Nobuyuki Takemura,Tatsuya Yamashita,Takeyuki Watadani,Masaki Kaibori,Shoji Kubo,M Shimada,Hiroaki Nagano,Etsuro Hatano,Hiroshi Aikata,Hiroko Iijima,Kazuomi Ueshima,Kazuyoshi Ohkawa,Takuya Genda,Kaoru Tsuchiya,Takuji Torimura,Masafumi Ikeda,Junji Furuse,Masaaki Akahane,Satoshi Kobayashi,Hideyuki Sakurai,Atsuya Takeda,Takamichi Murakami,Utaroh Motosugi,Yutaka Matsuyama,Masatoshi Kudo,Ryosuke Tateishi +26 more